Fertility and sterility
Audio Summaries

Possible therapeutic options for enhancing the number of oocytes in poor ovarian responders

Jun 22, 2026

The authors investigate potential therapeutic strategies to enhance oocyte yield in patients with poor ovarian response (POR), a condition often linked to low ovarian reserve and age-related infertility. They highlight the limitations of current treatment protocols and the lack of effective pharmacological options, proposing a multicycle stimulation approach to improve outcomes by increasing the number of available oocytes and embryos. The paper also discusses the controversial nature of non-pharmacological interventions and suggests future research directions for better management of POR.

Anti-Mullerian Hormone Rebound and Estradiol Changes in the Study of Women's Health Across the Nation

Jun 19, 2026

The authors aimed to characterize the prevalence of re-detectable anti-Mullerian hormone (AMH) during the menopause transition and its correlation with other ovarian hormones, particularly estradiol (E2). They found that nearly 54% of women experienced AMH rebound after reaching undetectable levels, with about half of these cases also showing a concurrent increase in E2, suggesting a potential resurgence of ovarian function. Factors such as younger age at the detectable limit of AMH, lower body mass index, and lower follicle-stimulating hormone levels were associated with this rebound, highlighting the variability of ovarian hormone levels during the perimenopausal period.

Male Factor Infertility Diagnoses, But Not Male Age, Significantly Affects the Yield of Usable Embryos in Donor Oocyte Cycles

Jun 17, 2026

The authors aimed to determine the effects of male age and male factor infertility on the yield of usable embryos in IVF cycles using donor oocytes. Their findings indicate that while male age does not significantly influence embryo suitability for transfer, the presence of male factor infertility diagnoses is associated with a reduced number of embryos available for transfer.

Home Pregnancy Test Sensitivity by Test Timing and Cycle Length with Real-World Use Among Pregnancy Planners who Conceived

Jun 16, 2026

The authors aimed to determine the sensitivity of home pregnancy tests based on the timing of testing relative to expected menses and menstrual cycle length among pregnancy planners who conceived. They found that testing too early, particularly two to four days before expected menses, resulted in a significant probability of false negatives, while sensitivity increased substantially after the expected period. Additionally, longer menstrual cycles were associated with higher test sensitivity, especially for early testers.

Infertility Treatment is Associated with Peripartum Hysterectomy: A Population-Based Cross-Sectional Study

Jun 15, 2026

This study investigates the association between infertility treatment and the risk of peripartum hysterectomy, considering factors such as placental complications, postpartum hemorrhage, maternal age, and race. The findings indicate that women who underwent infertility treatments have a higher risk of peripartum hysterectomy, particularly among certain racial and age groups, highlighting the need for increased monitoring and planning during pregnancy in this population.

Systematic assessment of allele dropout in preimplantation genetic testing for monogenic disorders: Incidence, detection, and clinical testing strategies

Jun 13, 2026

The authors aimed to systematically evaluate the incidence of allele dropout in preimplantation genetic testing for monogenic disorders (PGT-M) and to assess strategies to minimize its clinical impact. They found a 10.78% overall allele dropout rate, with significant differences in detection rates between next-generation sequencing (NGS) and Sanger sequencing methods. The study suggests that the NGS-based panel is a preferred first-line testing strategy, potentially allowing for the omission of routine Sanger sequencing in clinical practice.

Artificial intelligence in the in vitro fertilization laboratory: a committee opinion

Jun 12, 2026

This committee opinion explores the role of artificial intelligence (AI) in the in vitro fertilization (IVF) laboratory, particularly its potential impact on embryo selection. The authors aim to provide insights into the current state of AI implementation in IVF settings while emphasizing the need for caution in interpreting retrospective data, despite the large patient cohorts involved in studies.

Intergenerational fecundity and infertility: a cohort study

Jun 10, 2026

The authors aimed to determine whether parental time to pregnancy (TTP) and maternal history of infertility are linked to an increased risk of infertility in their adult children. The study found that longer parental TTP and a maternal history of infertility were associated with a higher risk of infertility in both sons and daughters, suggesting a potential intergenerational transmission of fertility issues. Further research is needed to confirm these findings and explore the underlying mechanisms.

Clinical Considerations in Donor Sperm Use

Jun 10, 2026

This review addresses the increasing use of donor sperm and the associated clinical considerations that clinicians must navigate, including medical, genetic, psychosocial, and regulatory factors. The authors aim to provide guidance on recipient evaluation, donor selection, and emerging challenges such as donor anonymity and the impact of direct-to-consumer genetic testing on donor-conceived individuals.

Reproductive Outcomes in Programmed Ovulatory versus Modified Natural Cycle FET: A Propensity Score-Matched Analysis of Prospective and Retrospective Cohorts

Jun 10, 2026

The authors aimed to compare reproductive outcomes between a new programmed ovulatory frozen-thawed embryo transfer protocol (PO-FET) and the traditional modified natural cycle (mNC) FET in normo-ovulatory women. Their analysis, which included 170 matched cycles from each group, found no significant differences in live birth rates, clinical pregnancy rates, or miscarriage rates between the two protocols. This suggests that the use of hCG may not be necessary, allowing for flexibility in protocol choice based on patient and clinician preferences.